These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15908015)

  • 21. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Abeta levels do not reflect brain Abeta levels.
    Freeman SH; Raju S; Hyman BT; Frosch MP; Irizarry MC
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):264-71. PubMed ID: 17413317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
    Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
    Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome.
    Matsubara E; Ghiso J; Frangione B; Amari M; Tomidokoro Y; Ikeda Y; Harigaya Y; Okamoto K; Shoji M
    Ann Neurol; 1999 Apr; 45(4):537-41. PubMed ID: 10211483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?
    Schoonenboom NS; Mulder C; Van Kamp GJ; Mehta SP; Scheltens P; Blankenstein MA; Mehta PD
    Ann Neurol; 2005 Jul; 58(1):139-42. PubMed ID: 15984010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of APP pathway mRNAs and proteins in Alzheimer's disease.
    Matsui T; Ingelsson M; Fukumoto H; Ramasamy K; Kowa H; Frosch MP; Irizarry MC; Hyman BT
    Brain Res; 2007 Aug; 1161():116-23. PubMed ID: 17586478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease.
    Kulstad JJ; Green PS; Cook DG; Watson GS; Reger MA; Baker LD; Plymate SR; Asthana S; Rhoads K; Mehta PD; Craft S
    Neurology; 2006 May; 66(10):1506-10. PubMed ID: 16717209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain.
    Aoki M; Volkmann I; Tjernberg LO; Winblad B; Bogdanovic N
    Neuroreport; 2008 Jul; 19(11):1085-9. PubMed ID: 18596605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma amyloid beta protein 1-42 levels in fetuses with Down syndrome.
    Bartha JL; Soothill PW
    Early Hum Dev; 2005 Apr; 81(4):351-4. PubMed ID: 15814219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neopterin and the risk of dementia in persons with Down syndrome.
    Coppus AM; Fekkes D; Verhoeven WM; Evenhuis HM; van Duijn CM
    Neurosci Lett; 2009 Jul; 458(2):60-4. PubMed ID: 19442877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer disease and Down syndrome: factors in pathogenesis.
    Lott IT; Head E
    Neurobiol Aging; 2005 Mar; 26(3):383-9. PubMed ID: 15639317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
    Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
    Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease.
    Sobów T; Flirski M; Kłoszewska I; Liberski PP
    Acta Neurobiol Exp (Wars); 2005; 65(2):117-24. PubMed ID: 15960295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma biomarkers of Alzheimer's disease.
    Kawarabayashi T; Shoji M
    Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
    Gurol ME; Irizarry MC; Smith EE; Raju S; Diaz-Arrastia R; Bottiglieri T; Rosand J; Growdon JH; Greenberg SM
    Neurology; 2006 Jan; 66(1):23-9. PubMed ID: 16401840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort.
    Blasko I; Jungwirth S; Jellinger K; Kemmler G; Krampla W; Weissgram S; Wichart I; Tragl KH; Hinterhuber H; Fischer P
    J Psychiatr Res; 2008 Sep; 42(11):946-55. PubMed ID: 18155247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.
    Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K
    Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.